@import url(http://finance.paidcontent.org/client/paidcontent/privatelabel.css);
February 22, 2012 at 07:13 AM EST
Hutchison MediPharma Starts Phase I Trial of Fourth Cancer Molecule
Hutchison MediPharma, the drug discovery company majority owned by Chi-Med, began a first-in-human Phase I clinical trial of a cancer drug, volitinib (HMPL-504), in Australia. Volitinib, the fourth cancer drug that the company has put into clinical trials, is a novel inhibitor of the c-Met receptor tyrosine kinase. In December 2011, Hutchison MediPharma entered a co-licensing agreement for the molecule with AstraZeneca in a $140 million deal. AstraZeneca assumed responsibility for developing volitinib outside of China. More details.... Stock Symbols: (AIM: HCM) (NYSE: AZN) Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});  
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here